NCT06897410 Reforça't: A Community, Social, and Healthcare Program for Patients With Cardiorespiratory Conditions Upon Hospital Discharge
| NCT ID | NCT06897410 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Corporació de Salut del Maresme i la Selva |
| Condition | Chronic Obstructive Lung Disease (COLD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-01-13 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized clinical trial is to determine whether an interdisciplinary, community-based intervention can reduce 30-day hospital readmissions and improve functional outcomes in patients aged 65 or older with chronic cardiac, respiratory, or mixed conditions following hospital discharge. The main questions it aims to answer are: Can the Reforça't program reduce 30-day hospital readmission rates to 25% compared to standard care? Does participation in Reforça't improve functional outcomes, medication adherence, quality of life, and mortality rates in this patient population? Researchers will compare patients enrolled in Reforça't (intervention group) with those receiving standard care (control group) to determine whether the program leads to lower readmission rates, improved health outcomes, and higher cost-effectiveness. Participants will: Undergo a pre- and post-intervention assessment (30 days post-discharge). Receive comprehensive, interdisciplinary care integrating medical, social, and rehabilitation services. Be monitored for 12 months to assess readmissions, survival, nursing home admissions, and overall well-being.
Eligibility Criteria
Inclusion Criteria: * Users admitted to the Polivalent Observation Units, Internal Medicine, or Hospital at home. * Individuals aged 65 years or older. * Hospital admission due to decompensation of a cardiac, respiratory, or mixed condition. * Place of residence within the health coverage area of Sant Jaume de Calella Hospital - Corporació de Salut del Maresme i la Selva. * Willingness to participate in the study as gathered by the signing of an informed consent document Exclusion Criteria: * Users institutionalized in a nursing home * Users already enrolled in home care programs * Users in the Advanced Chronic Care Model program with a limited life prognosis * Users on the waiting list for organ transplantation * Users with language barriers * Users with a GDS (Global Deterioration Scale) score of 5 or higher * Users who have already been included in the Reforça't program
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06897410 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Chronic Obstructive Lung Disease (COLD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06897410 currently recruiting?
Yes, NCT06897410 is actively recruiting participants. Contact the research team at gmanzano@salutms.cat for enrollment information.
Where is the NCT06897410 trial being conducted?
This trial is being conducted at Calella, Spain.
Who is sponsoring the NCT06897410 clinical trial?
NCT06897410 is sponsored by Corporació de Salut del Maresme i la Selva. The trial plans to enroll 200 participants.